Chemomab Therapeutics Ltd. (CMMB) stock
CMMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.14−0.41 (-26.45%)
Close on Nov 19, 2026Market cap $8.20MP/E 0.8Yield –
Chemomab Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Chemomab Therapeutics's free cash flow for the twelve months ending Jun 30, 2023 was -$25.68M. For fiscal 2025 it was -$11.13M. The highest annual figure on record is -$3.81M in fiscal 2016.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$11.13M | – |
| FY2024 | Dec 31, 2024 | -$15.39M | – |
| FY2023 | Dec 31, 2023 | -$23.61M | – |
| FY2022 | Dec 31, 2022 | -$20.44M | – |
| FY2021 | Dec 31, 2021 | -$12.61M | – |
| FY2020 | Dec 31, 2020 | -$5.28M | – |
| FY2019 | Dec 31, 2019 | -$16.55M | – |
| FY2018 | Dec 31, 2018 | -$14.44M | – |
| FY2017 | Dec 31, 2017 | -$8.55M | – |
| FY2016 | Dec 31, 2016 | -$3.81M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2023 | Jun 30, 2023 | -$7.49M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.19M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.70M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.30M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.71M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.73M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.03M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.58M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.71M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.30M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.56M | – |
| Q3 FY2020 | Sep 30, 2020 | -$921.00K | – |
| Q2 FY2020 | Jun 30, 2020 | -$880.00K | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.92M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.66M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.76M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.93M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.20M | – |
See a number that looks wrong?